QurAlis is a Cambridge, MA-based clinical-stage biotechnology company developing precision medicines for ALS and other neurodegenerative diseases with genetically validated targets. Led by CEO Kasper Roet, the company uses proprietary platforms and biomarkers to design drugs that act on disease-causing genetic alterations and enable patient selection. Its lead product candidates are QRL-201, a first-in-class therapy that aims to restore STMN2 expression and recently entered the clinic in the ANQUR trial (NCT05633459), and QRL-101, a selective Kv7.2/7.3 ion channel opener that began first-in-human dosing in a Phase 1 trial (NCT05667779) in December 2022. QurAlis will use the new funds to advance clinical development of QRL-201 and QRL-101, support ongoing and planned research, and advance additional pipeline candidates targeting components of ALS and genetically related frontotemporal dementia in defined patient populations. The company reported raising $88M in this Series B, bringing total funds raised to $143.5M. QurAlis focuses on developing precision therapeutics for ALS and genetically related FTD. The company leverages proprietary human stem cell technologies and lab-grown neuronal networks derived from cells of ALS patients to evaluate treatments targeting specific disease-causing mechanisms in patient sub-populations. Its strategy addresses mutations across more than 25 genes that can cause ALS and some forms of FTD. QurAlis intends to use recent funding to advance its lead programs into the clinic and continue developing ALS and FTD therapies. The company announced a $42 million Series A that brings total funding to $50.5 million. QurAlis is based in Cambridge, Mass. QurAlis develops precision therapeutics targeting genetically defined populations of ALS and frontotemporal dementia (FTD) patients. The company combines proprietary technology and patient-derived cells with medicinal chemistry and structure-based drug design to generate clinic-ready drug candidates. QurAlis is advancing multiple programs in preclinical research toward the clinic. Recent non-dilutive and strategic support includes a Pfizer-sponsored Golden Ticket and residency at Johnson & Johnson Innovation, JLABS. Management emphasizes targeting distinct disease mechanisms across the ALS/FTD spectrum enabled by human genetics and mechanistic insight. The company is based in Cambridge, Massachusetts.

Total raised

$131M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2023